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ABSTRACT
Objective To determine whether moderate hypothermia
after hypoxic-ischaemic encephalopathy in neonates
improves survival and neurological outcome at
18 months of age.
Design A meta-analysis was performed using a fixed
effect model. Risk ratios, risk difference, and number
needed to treat, plus 95% confidence intervals, were
measured.
Data sources Studies were identified from the Cochrane
centralregisterofcontrolledtrials,theOxforddatabaseof
perinataltrials,PubMed,previousreviews,andabstracts.
Review methods Reports that compared whole body
cooling or selective head cooling with normal care in
neonates with hypoxic-ischaemic encephalopathy and
that included data on death or disability and on specific
neurological outcomes of interest to patients and
clinicians were selected.
ResultsWefoundthreetrials,encompassing767infants,
that included information on death and major
neurodevelopmental disability after at least 18 months’
follow-up. We also identified seven other trials with
mortality information but no appropriate
neurodevelopmental data. Therapeutic hypothermia
significantly reduced the combined rate of death and
severe disability in the three trials with 18 month
outcomes (risk ratio 0.81, 95% confidence interval 0.71
to 0.93, P=0.002; risk difference −0.11, 95% CI −0.18 to
−0.04),withanumberneededtotreatofnine(95%CI5to
25). Hypothermia increased survival with normal
neurologicalfunction(riskratio1.53,95%CI1.22to1.93,
P<0.001;riskdifference0.12,95%CI0.06to0.18),witha
number needed to treat of eight (95% CI 5 to 17), and in
survivorsreducedtheratesofseveredisability(P=0.006),
cerebral palsy (P=0.004), and mental and the
psychomotor developmental index of less than 70
(P=0.01 and P=0.02, respectively). No significant
interaction between severity of encephalopathy and
treatment effect was detected. Mortality was significantly
reduced when we assessed all 10 trials (1320 infants;
relative risk 0.78, 95% CI 0.66 to 0.93, P=0.005; risk
difference −0.07, 95% CI −0.12 to −0.02), with a number
needed to treat of 14 (95% CI 8 to 47).
Conclusions In infants with hypoxic-ischaemic
encephalopathy, moderate hypothermia is associated
with a consistent reduction in death and neurological
impairment at 18 months.
Perinatalhypoxic-ischaemicencephalopathyisamajor
cause of death and disability worldwide for which no
specific therapy has been available.
1 Studies have
shown that neural damage after hypoxia-ischaemia is
delayed for several hours and that treatment with pro-
longed moderate hypothermia reduces cerebral injury
and improves neurological outcome.
2 Several clinical
trialsoftheapplicationoftherapeutichypothermiadur-
ing perinatal hypoxic-ischaemic encephalopathy have
been reported.
3-6 Unfortunately, the results of these
trials are not conclusive—the few studies that report
neurological outcomes at 18 months of age or more
useacompositeprimaryoutcomeofdeathordisability,
which makes precise interpretation difficult. In addi-
tion, although the studies produce point estimates that
show a treatment benefit, the estimates only reach con-
ventional statistical significance in one report.
5
A systematic review published by the Cochrane
Library in 2007 concluded that 72 hours of moderate
hypothermiastartedwithin6hoursofbirthreducesthe
rate of death and disability at 18 months of age.
7
Expertsandclinicianswerehesitantaboutthisfinding,
however,becausethedatawereincompleteandinade-
quate topermitany commentonneurodevelopmental
outcomes in survivors or to address important issues
such as whether the efficacy of hypothermia is moder-
ated by the severity of encephalopathy.
Consequently, controversy exists over the value of
hypothermia after hypoxic-ischaemic encephalopa-
thy, and consensus has not been reached. A workshop
convenedbytheNationalInstituteofChildHealthand
Human Development in 2006 concluded that
1Institute of Clinical Sciences,
Faculty of Medicine, Imperial
College London, London SW7 2AZ
2Medical Research Council Clinical
Sciences Centre, Hammersmith
Hospital, Imperial College London,
London W12 0NN
3National Perinatal Epidemiology
Unit, Department of Public Health,
University of Oxford, Oxford
OX3 7LF
4Department of Physiology,
School of Medical Sciences,
University of Auckland, Auckland
1142, New Zealand
5Royal Jubilee Maternity Service,
Royal Maternity Hospital, Belfast
BT12 6BA
6Department of Child Health,
Queen’s University of Belfast,
Belfast BT12 6BL
7University of Leeds, Leeds
LS1 3BR
8Leeds General Infirmary, Leeds
LS1 3EX
9Department of Clinical Science at
South Bristol, Faculty of Medicine
and Dentistry, University of
Bristol, St Michael’sH o s p i t a l ,
Bristol BS2 8EG
Correspondence to: D Azzopardi
d.azzopardi@imperial.ac.uk
Cite this as: BMJ 2010;340:c363
doi:10.1136/bmj.c363
BMJ | ONLINE FIRST | bmj.com page 1 of 7therapeutic hypothermia was an evolving therapy and
theevidencewasnotsufficienttosupportmakingitthe
standard of care.
8 This view was endorsed by the
American Academy of Pediatrics committee on the
fetus and newborn.
9
New studies have been published since the
Cochrane review was conducted, including the Total
Body Hypothermia (TOBY) trial, the largest rando-
mised controlled trial of hypothermia for perinatal
encephalopathy.
6TheTOBYtrialreportstheneurolo-
gical outcome of 325 infants at 18 months of age, but
doesnotprovideconclusiveevidenceontheefficacyof
therapeutic hypothermia because it failed to detect a
significant benefit regarding the primary outcome of
death or disability.
Wereportameta-analysisofnewstudiesandrecently
available additional data from previously reported stu-
dies that defines the confidence with which therapeutic
hypothermiamightbeusedtoreducedeathanddisabil-
ity after hypoxia-ischaemia, determines its effect on
neurological outcomes in infants who survive perinatal
hypoxic-ischaemic encephalopathy, and considers
whether the therapeutic effect is restricted to infants
with moderate encephalopathy.
METHODS
Relevant studies were identified from the Cochrane
central register of controlled trials, the Oxford data-
base of perinatal trials, PubMed (using the Mesh
terms (“Infant, Newborn” AND “Hypoxia-Ischemia,
Brain”) and “Hypothermia, Induced”), previous
reviews, and abstracts up to July 2009, and additional
unpublished data were sought and obtained from
investigatorsofpublishedstudiesandunpublishedstu-
dies. The identification of studies was carried out by
members of our study group, and the selection of rele-
vant studies was by consensus.
We assessed the methodological quality of the stu-
dies according to whether they used randomisation
and blinding to the intervention and on the basis of
completeness and blinding of follow-up, as recom-
mendedbytheneonatalreviewgroupoftheCochrane
Collaboration.
10 We selected reports that included
dataondeathordisabilityandonspecificneurological
outcomes of interest to patients and clinicians, such as
cerebral palsy or survival with normal neurological
function. We used this dataset to examine the effect
of prolonged moderate hypothermia on the following
outcomes: the combined rate of death and disability;
the rate of survival without neurological abnormality;
the rate of severe disability; the rate of cerebral palsy;
scoresonthe mentaldevelopmentalandpsychomotor
indices of the Bayley scales of infant development
11;
and the quality of vision and hearing.
Weusedallstudiesthatreportedmortalitytoanalyse
the effect of hypothermia on mortality. This decision
was based on our reasoning that the majority of deaths
from perinatal hypoxic-ischaemic encephalopathy
would occur in the neonatal period, thus mortality
would be appropriately captured even when follow-up
did not continue until 18 months of age. To analyse
neurological outcomes, we selected completed rando-
mised controlled trials that assessed neurological out-
comes to at least 18 months of age. Composite
neurological outcomes are reported for all infants ran-
domly allocated to a study arm, with the number of
infants not followed up included in the denominator
when calculating the rates of the composite outcomes.
Individual neurological outcomes are reported for sur-
vivors with available follow-up data.
Meta-analysiswasperformedwiththeReviewManager
software(RevManVersion5.0;NordicCochraneCentre,
Copenhagen, Denmark) using the Mantel-Haenszel
methodandafixedeffectmodel.Wecalculatedriskratios
and risk difference for dichotomous variables, with 95%
confidence intervals, and the number needed to treat,
which is the reciprocal of the risk difference, with 95%
confidence intervals.
Todeterminewhetherthebenefitofhypothermiaon
death or disability was affected by the severity of ence-
phalopathy, we examined subgroups for which the
severity of encephalopathy was graded as moderate
or severe on the basis of clinical examination and/or
amplitude integrated electroencephalography in trials
that reported neurological outcome at 18 months of
age or more. Grade of encephalopathy assessed by
amplitude integrated electroencephalography consid-
ered to be equivalent to that of the clinical assessment.
The consistency of the treatment effect across sub-
groupswasexploredbycalculatingtheratioofrelative
risks with 95% confidence interval.
12
All statistical tests were two sided and not adjusted
formultiplecomparisons.APvalue<0.05wasconsid-
eredstatisticallysignificant.Weexaminedheterogene-
ity among studies by using the χ
2 and the I
2 tests.
RESULTS
We compiled a dataset of 1320 infants from 10 rando-
misedcontrolledtrialsforwhomatleastmortalitydata
wereavailable.
3-613-18Asimplifiedsummaryofthetrial
characteristics is provided in table 1.
Neurological outcomes up to at least 18 months of
age were available for a subset of three trials compris-
ing 767 infants: a trial by the CoolCap study group,
4 a
National Institute of Child Health and Human Devel-
opment (NICHD) study,
5 and the TOBY trial.
6 These
three trials had similar entry criteria: evidence of birth
asphyxia; and moderate or severe encephalopathy.
The entry criteria for the CoolCap and TOBY trials
also included abnormal amplitude integrated electro-
encephalogram. Infants were at least 36 weeks’ gesta-
tion at recruitment, and random allocation was
completed by 6 hours after birth. In the CoolCap
study, cooling was achieved by circulating cooling
fluid in a cap, with a target rectal temperature of 34.5°
C, and wasmaintained for 72 hours. In the TOBY and
NICHD trials, whole body cooling to 33.5°C was
induced by cooling blankets placed under the infants.
Two other pragmatic trialswitha plannedfollow-up
at 18 months were in progress at the time of our
meta-analysis and had not yet reported their results in
full: the Infant Cooling Evaluation (ICE) trial, which
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follow-upbylate2009,
13andtheneo.nEURO.network
trial of 129 infants, which has not yet been fully ana-
lysed or reported.
14 One randomised pilot study of 36
infants carried out in Uganda reported outcomes to
17 days of age.
15 The trials carried out in China that
were included in previous systematic reviews have
still not reported 18 month outcomes.
1619 Further
explanatory data from previously analysed trials have
been published or were made available specifically for
the present review.
62021
We excluded from the analysis a report of 31 rando-
mised infants who were part of a series of studies that
alsoincludedinfantswhowereassignedtreatmentona
non-random basis and were treated with varying
degrees of hypothermia.
2223 One trial of 65 infants
that reported outcome only to 12 months of age was
excluded from the analysis of neurological outcomes
but was included in the analysis of mortality data.
3
Methodological quality of the dataset
In the three trials that report neurological outcomes to
18 months, none blinded caregivers to the treatment
assignment. Follow-up to at least 18 months of age by
assessors masked to allocation was available for 218
(93%) of the 234 infants in the CoolCap trial, 205
(99%) of the 208 infants in the NICHD trial, and 323
(99%) of the 325 infants in the TOBY trial.
The methodological quality of six of the 10 trials
included in the assessment of mortality was reported
in a 2007 Cochrane review
7; allocation concealment
was considered inadequate in the study of Lin et al.
16
The four remaining studies used appropriate
methodology.
613-15
Primary outcome: death or disability at 18 months
The primary outcome for all three trials was the com-
bined rate of mortality and disability. Disability was
defined in the CoolCap and TOBY trials as the pre-
sence of at least one of the following impairments:
mental development index score of less than 70 (that
is, 2 standard deviations from a standardised mean of
100) on the Bayley scales of infant development; gross
motor function classification system level 3-5 (where
thescaleisfrom1to5,with1beingthemildestimpair-
ment); or bilateral cortical visual impairment with no
useful vision. The NICHD trial defined disability as a
mentaldevelopmentalindexscoreof70-84plusoneor
more of the following impairments: gross motor func-
tion classification system level 2; hearing impairment
with no amplification; or a persistent seizure disorder.
Each of these three trials showed a reduction in the
risk of mortality and disability in infants who under-
went therapeutichypothermia,but thefindingwassta-
tistically significant only in the NICHD trial (fig 1).
Meta-analysis of the three trials showed that therapeu-
tic hypothermia significantly reduced the risk of death
Table 1 |Summary of randomised trials of moderate hypothermia for perinatal hypoxic-ischaemic encephalopathy
Study
Ratio cooled:
controls
Cooling
method
Core temperature
achieved (°C)
Duration of
cooling (hours) Primary outcome Follow-up period
Eicher et al, 2005
3 32:33 Systemic 33 48 Rates of death and severe disability 12 months
CoolCap trial
(Gluckman et al, 2005)
4
116:118 Selective 34-35 72 Rates of death and severe disability 18 months
NICHD trial
(Shankaran et al, 2005)
5
102:106 Systemic 33.5 72 Rates of death, moderate disability, and severe
disability
18 months
TOBY trial
(Azzopardi et al, 2009)
6
163:162 Systemic 33-34 72 Rates of death and severe disability 18 months
ICE trial
(Jacobs et al, 2008)
13
110:111 Systemic 33-34 72 Rates of death and severe disabilities 24 months
neo.nEURO.network trial
(Simbruner et al, 2008)
14
64:65 Systemic 33-34 72 Rates of death and severe disability 18 months
Robertson et al, 2008
15 21:15 Systemic 33-34 72 Mortality, neurological assessment, and seizures 17 days
Lin et al, 2006
16 32:30 Selective 34-35 72 Findings on computed tomogram and
neurological assessment
7-10 days
Akisu et al, 2003
17 11:10 Selective 36.5 72 Levels of platelet activating factor in
cerebrospinal fluid
4-10 days
Shankaran et al, 2002
18 9:10 Systemic 34.5 72 Clinical course until hospital discharge Until hospital
discharge
Abbreviations: ICE, Infant Cooling Evaluation; NICHD, National Institute of Child Health and Human Development; TOBY, Total Body Hypothermia.
  TOBY
  NICHD
  CoolCap
Total (95% CI)
Total events
0.86 (0.68 to 1.07)
0.73 (0.56 to 0.95)
0.82 (0.65 to 1.03)
0.81 (0.71 to 0.93)
39.0
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Fig 1 | Forest plot of the effect of therapeutic hypothermia compared with standard care
(normothermia) on death or disability (“events”). All infants randomly assigned to either study
arm were included in the analysis. A Mantel-Haenszel fixed effects model was used to
calculate risk ratios and 95% confidence intervals. Test for heterogeneity: χ
2=0.82, degrees of
freedom=2( P =0.66); I
2=0%. Test for overall effect: Z=3.03 (P=0.002). Studies shown are the
Total Body Hypothermia (TOBY) trial,
6 the National Institute of Child Health and Human
Development (NICHD) trial,
5 and the CoolCap trial
4
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0.71 to 0.93, P=0.002; risk difference −0.11, 95% CI
−0.18 to −0.04), with a number needed to treat of
nine (95% CI 5 to 25).
Secondary outcomes
Meta-analysis of the CoolCap, NICHD, and TOBY
trialsshowedthattreatmentwithhypothermiawascon-
sistentlyassociatedwithanincreasedrateofnormalsur-
vival, defined as survival without cerebral palsy and
with a mental developmental index score of more than
84, a psychomotor development index score of more
than 84, and normal vision and hearing (fig 2; relative
risk 1.53, 95% CI 1.22 to 1.93, P<0.001; risk difference
0.12, 95% CI 0.06 to 0.18), with a number needed to
treat of eight (95% CI 5 to 17). Among infants who sur-
vivedto18months ofage,those treatedwithhypother-
mia had significantly lower rates of severe disability
(P=0.006),cerebralpalsy(P=0.004),severeneuromotor
delay (psychomotor developmental index score <70;
P=0.02), severe neurodevelopmental delay (mental
developmentalindexscore<70;P=0.01),andblindness
(P=0.03; table 2). The rate of deafness was 4.7% (12/
255) in infants treated with hypothermia and 6% (14/
227) in controls (P=0.47). I
2 was 0% for all analyses of
neurological outcomes, indicating no heterogeneity
among studies (fig 3).
Analysis of data from all 10 trials that reported mor-
tality rates showed that infants treated with prolonged
moderate hypothermia were less likely to die than
those who received normal care (fig 4). A total of 169
(26%) of the 660 infants treated with therapeutic
hypothermia died, compared with 217 (33%) of the
660 infants who received standard care (relative risk
0.78, 95% CI 0.66 to 0.93, P=0.005; risk difference
−0.07, 95% CI −0.12 to −0.02), with a number needed
to treat of 14 (95% CI 8 to 47). Only the Uganda study
showed an excess mortality in infants who underwent
therapeutichypothermia(7/21cooledinfantsdiedv1/
15 non-cooled infants).
15
Effect of severity of encephalopathy
The severity of encephalopathy at random allocation
was assessed by amplitude of integrated electroence-
phalogram and by clinical assessment in the CoolCap
study,byclinicalassessmentonlyintheNICHDstudy,
and by amplitude of integrated electroencephalogram
only in the TOBY trial. For the CoolCap study, we
used only the clinical assessment of encephalopathy
for our meta-analysis because this outcome was
comparable with that used in the NICHD study.
20
Meta-analysisshowedthattherelativeriskforthecom-
bined outcome of death or severe disability was lower
in infants with moderate encephalopathy (0.73, 95%
CI 0.58 to 0.92; P=0.008) than in those with severe
encephalopathy (0.87, 95% CI 0.75 to 1.01; P=0.07;
fig 5). The test for interaction effect was not significant
(ratio of relative risks 0.83, 95% CI 0.63 to 1.09;
Z=1.34, P=0.18).
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  TOBY
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Fig 2 | Forest plot of the effect of therapeutic hypothermia compared with standard care
(normothermia) on survival with normal neurological function (“events”). All infants randomly
assigned to either study arm were included in the analysis. A Mantel-Haenszel fixed effects
model was used to calculate risk ratios and 95% confidence intervals. Test for heterogeneity:
χ
2=0.05, degrees of freedom=2( P =0.66); I
2=0%. Test for overall effect: Z=3.66 (P=0.0003).
Studies shown are the Total Body Hypothermia (TOBY) trial,
6 the National Institute of Child
Health and Human Development (NICHD) trial,
5 and the CoolCap trial
4
Table 2 |Effect of moderate hypothermia on neurological outcomes at 18 months compared with controls
Risk ratio
(95% CI)
Risk difference
(95% CI)
Number needed
to treat (95% CI) P value
Death or severe disability* 0.81 (0.71 to 0.93) −0.11 (−0.18 to −0.04) 9 (5 to 25) 0.002
Survival with normal outcome† 1.53 (1.22 to 1.93) 0.12 (0.06 to 0.18) 8 (5 to 17) <0.001
Mortality 0.78 (0.66 to 0.93) −0.07 (−0.12 to −0.02) 14 (8 to 47) 0.005
Severe disability in survivors* 0.71 (0.56 to 0.91) − 0.11 (−0.20 to −0.03) 9 (5 to 30) 0.006
Cerebral palsy in survivors 0.69 (0.54 to 0.89) −0.12 (−0.20 to −0.04) 8 (5 to 24) 0.004
Severe neuromotor delay in survivors‡ 0.73 (0.56 to 0.95) −0.10 (−0.18 to −0.02) 10 (6 to 71) 0.02
Severe neurodevelopmental delay in survivors§ 0.71 (0.54 to 0.92) −0.11 (−0.19 to −0.03) 9 (5 to 39) 0.01
Blindness in survivors 0.57 (0.33 to 0.96) −0.06 (−0.11 to 0.00) 17 (9 to 232) 0.03
Deafness in survivors 0.76 (0.36 to 1.62) −0.01 (−0.05 to 0.03 NA 0.47
*Severe disability was defined in the CoolCap and TOBY trials as the presence of at least one of the following impairments: mental development
index score of less than 70 (2 standard deviations below the standardised mean of 100) on the Bayley scales of infant development; gross motor
function classification system level 3-5 (where the scale is from 1 to 5, with 1 being the mildest impairment); or bilateral cortical visual impairment
with no useful vision. The NICHD trial defined disability as a mental developmental index score of 70-84 plus one or more of the following
impairments: gross motor function classification system level 2; hearing impairment with no amplification; or a persistent seizure disorder
†Survival with normal outcome was defined as survival without cerebral palsy and with a mental developmental index score of more than 84, a
psychomotor developmental index score of more than 84, and normal vision and hearing.
‡Severe neuromotor delay was determined on the basis of a psychomotor developmental index score of less than 70 in survivors.
§Severe neurodevelopmental delay was determined on the basis of a mental developmental index score of less than 70 in survivors.
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In the absence of any specific intervention to improve
the dismal prognosis of infants with hypoxic-ischaemic
encephalopathy, clinical enthusiasm for a novel treat-
ment is understandable. However, individual trials do
not provide unequivocal evidence of benefit from ther-
apeutichypothermia:twoofthethreestudiesthatreport
neurological outcome at 18 months or more failed to
detect a significant improvement in the primary out-
come; differences exist in the apparent effect of
hypothermiaonimportantoutcomessuchasmortality;
and uncertainty persists concerning the influence of
clinical factors, such as disease severity, on treatment
effect. These issues led to controversy and divergent
viewsonthevalueoftherapeutichypothermiaininfants
with hypoxic-ischaemic encephalopathy.
24-28 This new
meta-analysisoftheexistingdataonthetopic,including
the results of the TOBY trial, provides the highest level
evidence that moderate hypothermia is efficacious in
infants with hypoxic-ischaemic encephalopathy.
The completed trials included in this analysis were of
high methodological quality, but none was able to blind
treatment assignment; neurodevelopmental assessment,
however, was masked in all the studies. The point esti-
matesoftreatmenteffectforprimaryandmostsecondary
outcomes showed a striking consistency both between
outcomes and across the trials. The risk ratio assigned
to the primary outcome of death or disability in the
three major trials was very similar, although in two trials
the 95% confidence intervals crossed unity. Our meta-
analysis,however,confirmsthattheoveralleffectofther-
apeutic hypothermia in infants with hypoxic-ischaemic
encephalopathy is significant.
This uniformity is also seen in a number of second-
ary measures of neurodevelopmental outcome—in
particular the rate of “normal” survival, where the
point estimates for risk ratio were almost identical
across the trials (although only significant in one
study). Taken together, the homogeneity of the trial
resultsgivesa highlevelofconfidenceinthetherapeu-
tic benefit of prolonged moderate hypothermia.
Our findings are particularly remarkable given the
differences between the studies in cooling method and
trial protocol. All the three trials that reported neuro-
logical outcome at 18 months or more reduced whole
body temperature as measured in the rectum or oeso-
phagus, but the core temperature of 33-34°C in the
TOBYandtheNICHDtrialswasachievedbydifferent
coolingblanketsandthetemperatureof34-35°Cinthe
CoolCap study by using head cooling. The TOBY
trial, but not the NICHD or CoolCap trials, cooled
infants during transport to the treatment centre, but
the age at start of cooling was similar in the three stu-
dies. The minimal effect of these differences increases
confidence that our findings can be generalised to the
wider healthcare system and suggests that clinicians
planning the widespread implementation of therapeu-
tic hypothermia need be less concerned about the pre-
cisemethodofcoolingandmorefocusedontrainingof
staff for its safe application.
Influence of severity of encephalopathy
An important question raised by clinicians caring for
infants with hypoxic-ischaemic encephalopathy, and
onetowhichindividualtrialsofferdiscrepantanswers,
is whether it is possible to define a group of patients
whoaretooseverelyaffectedtobenefitfromtreatment
with hypothermia, as was suggested by the CoolCap
study.
4 To shed light on thisissue we carriedout a sub-
group analysisto examinethe interaction betweendis-
ease severity and treatment effect. The primary
outcome of death or disability at 18 months was
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Fig 3 | Forest plot of the effect of therapeutic hypothermia compared with standard care
(normothermia) on neurological outcomes (“events”). All infants surviving to 18 months
randomly assigned to either study arm were included in the analysis. A Mantel-Haenszel fixed
effects model was used to calculate risk ratios and 95% confidence intervals. Studies shown
are the Total Body Hypothermia (TOBY) trial,
6 the National Institute of Child Health and Human
Development (NICHD) trial,
5 and the CoolCap trial.
4 Abbreviations: MDI, mental developmental
index score; PDI, psychomotor developmental index score
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affected infants but not in severely affected babies.
Until further data are available to clarify the effect of
therapeutic hypothermia in infants with severe ence-
phalopathy, the evidence may appropriately be inter-
preted to mean that although there is considerable
confidencethatinfantswithmoderateencephalopathy
will benefit overall from therapeutic hypothermia, it
remains appropriate for clinicians to make individual
decisions on whether to treat infants with severe ence-
phalopathy.
Limitations of study data
Somecaveatsshouldbeacknowledgedwhenconsider-
ingtheevidencethathypothermiashouldbeofferedin
the first 6 hours of life for infants with moderate to
severe hypoxic-ischaemic encephalopathy. Firstly, no
study has yet reported outcomes in later childhood
after therapeutic hypothermia. Eighteen months is
probably the earliest age at which a comprehensive
assessmentcan be reliablycarriedout, althoughdetec-
tion of cognitive and behavioural problems requires
assessment later in childhood.
29 Infants in the trials
reported to date should be followed up to confirm
that the neurological data recordedat 18 months accu-
ratelypredictlongtermneurologicalfunction,particu-
larly given that the current data make it unlikely that
further randomised trials will be conducted in well
resourced health economies.
Secondly,twofurthertrialsontherapeutichypother-
mia for hypoxic-ischaemic encephalopathy are yet to
report results, which might affect the conclusions of
our study. However, the number of infants in the cur-
rent meta-analysis (767 infants with neurological out-
come reported at 18 months of age or more) is more
than double that in the trials whose results are awaited
(350infants).Largetrialsthatshowaverylargeadverse
effect of treatment would be required for the conclu-
sions of the current meta-analysis to be materially
changed;giventhestrikinghomogeneityofthecurrent
dataset, such findings can be regarded as unlikely.
Indeed, preliminary presentation of these trials
suggests that they also show a benefit from
hypothermia.
1516
Thirdly, the present data cannot necessarily be
extrapolated to resource poor environments, given
thatcare available,risk benefits,and costsoftreatment
are likely to differ from those in the settings of the stu-
dies that were analysed. The only study to report on
hypothermic neural rescue in such an environment is
apilotstudyinUgandathatreportedincreasedmortal-
ity in the treatment group.
17 This finding appears to
reflect chance allocation of more infants with severe
encephalopathy to the treatment group. Furthermore,
it isinterestingtonote thatthe greatmajorityofinfants
in this small study were hypothermic at the time of
randomisation, which may well affect the potential
for further benefit. Although this point is not evidence
that coolingis inappropriate in resourcepoor environ-
ments, it emphasises the importance of field trials in
different environments and underlines the need to
ensure that therapeutic hypothermia is only applied
in the manner that has been tested in well conducted
clinical trials (that is, with access to specialist newborn
services and appropriate training and equipment).
Conclusion
The present analysis strongly supports the use of thera-
peutic hypothermia in newborn infants with hypoxic-
ischaemic encephalopathy to reduce the risk of death
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Fig 4 | Forest plot of the effect of therapeutic hypothermia compared with standard care
(normothermia) on mortality (“events”) in all 10 trials identified. Studies shown are Akisu et al
(2003),
17 the CoolCap trial,
4 Eicher et al (2005),
3 the Infant Cooling Evaluation (ICE) trial,
13 Lin
et al (2006)
16 the neo.nEURO.network trial,
14 the National Institute of Child Health and Human
Development (NICHD) study,
5 Robertson et al (2008),
15 Shankaran et al (2002),
18 and the Total
Body Hypothermia (TOBY) trial.
6 All infants randomly assigned to either study arm were
included in the analysis. A Mantel-Haenszel fixed effects model was used to calculate risk
ratios and 95% confidence intervals. Test for heterogeneity: χ
2=7.73, degrees of freedom=9
(P=0.56); I
2=0%. Test for overall effect: Z=2.89 (P=0.005)
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Assessment of grade of encephalopathy was by amplitude integrated electroencephalogram
and clinical examination in the CoolCap
4 and National Institute of Child Health and Human
Development (NICHD)
5 studies and by amplitude integrated electroencephalogram only in the
Total Body Hypothermia (TOBY) study.
6 All infants randomly assigned to either study arm were
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page 6 of 7 BMJ | ONLINE FIRST | bmj.comand neurological impairment at 18 months. Continued
follow-upofthechildrenenrolledinthestudiesincluded
in our meta-analysis is essential to determine whether
these benefits are maintained in later childhood.
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What is already known on this topic
Prolonged moderate hypothermia is increasingly used to treat infants with hypoxic-
ischaemic encephalopathy
It is uncertain whether therapeutic hypothermia improves important neurological
outcomes, such as the rate of cerebral palsy, after perinatal asphyxia
What this study adds
Prolonged moderate hypothermia improves survival and reduces the rate of disability at
18 months of age in infants who survive hypoxic-ischaemic encephalopathy
The remarkable homogeneity of trial results provides unequivocal evidence of therapeutic
benefit of prolonged moderate hypothermia
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